Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC

Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC is a phase 2/3, randomised interventional study registered as NCT07596290 by Beijing Friendship Hospital, with a registry enrolment figure of 342 participants, started 2026-07-15 and due to reach its primary completion in 2028-12-31. Interventions recorded: Short-course radiotherapy; Long-course radiotherapy; Immunotherapy. Conditions listed: Locally Advanced Rectal Adenocarcinoma; Neoadjuvant Chemoradiation; Neoadjuvant Immunotherapy. Primary outcome: Complete response. Colorectal eligibility wording from the registry: "Histopathologically confirmed rectal adenocarcinoma via colonoscopy; pMMR or MSS phenotype;". No results are recorded here; the registry entry is the source.